The Danish drugmaker’s arch-rival Eli Lilly & Co. has introduced another shot — Zepbound, also known as Mounjaro — that so ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" during ...

Both Ozempic and Wegovy are forms of semaglutide ... This news comes less than a month after Mounjaro and Zepbound, also ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Medically reviewed by Kristie Reed, PharmD Wegovy (semaglutide) is an injectable medication that is FDA-approved for obesity management and weight loss in people over age 12. Your healthcare provider ...

Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...